In our recent study, we indicated that BMP receptor inhibitors are therapeutic agents that can potentially inhibit the cancer stem cell-related processes in HCC, including tumor progression, recurrence, and metastasis, by inhibiting BMP9-ID1 signaling [9]. The gene discussed is GDF2; the disease is neoplasm.